title: QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
authors.affiliation: Department of Paediatric Endocrinology, Leeds General Infirmary, Leeds, West Yorkshire, UK Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, York, UK.
authors.forename: Nadia Laila
authors.initials: NL
authors.lastname: Amin
authors.affiliation: Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, York, UK.
authors.forename: Rebecca M
authors.initials: RM
authors.lastname: James
authors.affiliation: Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, York, UK Centre for Reviews and Dissemination, York, UK.
authors.forename: Robert
authors.identifier: http://orcid.org/0000-0002-4938-9673
authors.initials: R
authors.lastname: Phillips
mesh_terms: D000293:Adolescent; D019386:Alendronate / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010020:Osteonecrosis / Q000139:chemically induced / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D000077268:Pamidronate; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D000068296:Risedronic Acid / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D000077268:Pamidronate; D019386:Alendronate
keywords: Bone Disease; Evidence Based Medicine; General Paediatrics; Musculo-Skeletal; Paediatric Practice